Cytek BioSciences, Inc. (NASDAQ:CTKB) gapped down before the market opened on Wednesday . The stock had previously closed at $26.78, but opened at $25.96. Cytek BioSciences shares last traded at $25.86, with a volume of 204 shares trading hands.
A number of research firms have commented on CTKB. The Goldman Sachs Group initiated coverage on shares of Cytek BioSciences in a research report on Tuesday, August 17th. They issued a “buy” rating and a $28.00 target price for the company. Morgan Stanley started coverage on shares of Cytek BioSciences in a research report on Tuesday, August 17th. They issued an “equal weight” rating and a $26.00 target price on the stock. Cowen assumed coverage on shares of Cytek BioSciences in a research note on Tuesday, August 17th. They issued an “outperform” rating on the stock. Finally, Piper Sandler assumed coverage on Cytek BioSciences in a research report on Tuesday, August 17th. They issued an “overweight” rating and a $28.00 price target on the stock.
About Cytek BioSciences (NASDAQ:CTKB)
Cytek Biosciences Inc provides cell analysis solutions. The company developed high-resolution, high-content and high-sensitivity cell analysis technology called Full Spectrum Profiling. Cytek Biosciences Inc is based in FREMONT, Calif.
See Also: What is basic economics?
Receive News & Ratings for Cytek BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.